RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Jazz Pharmaceuticals and slightly raised the price target from $174 to $175.
October 04, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its 'Outperform' rating for Jazz Pharmaceuticals and increased the price target marginally from $174 to $175, indicating continued confidence in the company's performance.
The reaffirmation of the 'Outperform' rating and the slight increase in the price target suggest positive sentiment from RBC Capital towards Jazz Pharmaceuticals. This could lead to a short-term positive impact on the stock price as investors may view the analyst's confidence as a sign of potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100